

August 4, 2023



Medexus to Participate in Fireside Chat at SHARE Series Event

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 4, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.

Event: SHARE Series

Date: August 14, 2023

Location: Virtual Presentation

Medexus Presentation: Monday, August 14 at 8:30 AM Eastern time

Ken d'Entremont, Medexus's Chief Executive Officer, and Marcel Konrad, Medexus's Chief Financial Officer, will conduct a 30-minute moderated fireside chat at 8:30 AM Eastern time. This fireside chat will include the opportunity for questions.

The live stream of the Medexus presentation will be available on the Investors—News & Events section of Medexus's corporate website or at the following link:

<https://www.openexchange.tv/share-series>

An archived replay will be available on the SHARE Series website for approximately 90 days following the event.

About Medexus

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.

Contacts

Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com

Marcel Konrad | CFO, Medexus Pharmaceuticals
Tel: 312-548-3139 | Email: marcel.konrad@medexus.com

Victoria Rutherford | Adelaide Capital

Tel: 480-625-5772 | Email: victoria@adcap.ca

Forward-looking statements

Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (**forward-looking statements**). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Given these risks, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/176057>

SOURCE Medexus Pharmaceuticals Inc.